Drug Type Small molecule drug |
Synonyms Spebrutinib (USAN/INN), Spebrutinib Besylate, AVL-292 + [1] |
Target |
Mechanism BTK inhibitors(Tyrosine-protein kinase BTK inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC22H22FN5O3 |
InChIKeyKXBDTLQSDKGAEB-UHFFFAOYSA-N |
CAS Registry1202757-89-8 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Rheumatoid Arthritis | Phase 2 | US | 01 Oct 2013 | |
Diffuse Large B-Cell Lymphoma | Phase 1 | US | 18 Dec 2013 | |
Diffuse Large B-Cell Lymphoma | Phase 1 | CA | 18 Dec 2013 | |
Diffuse Large B-Cell Lymphoma | Phase 1 | FR | 18 Dec 2013 | |
Diffuse Large B-Cell Lymphoma | Phase 1 | IT | 18 Dec 2013 | |
Follicular Lymphoma | Phase 1 | US | 18 Dec 2013 | |
Follicular Lymphoma | Phase 1 | CA | 18 Dec 2013 | |
Follicular Lymphoma | Phase 1 | FR | 18 Dec 2013 | |
Follicular Lymphoma | Phase 1 | IT | 18 Dec 2013 | |
Recurrent Chronic Lymphoid Leukemia | Phase 1 | US | 01 Dec 2012 |
Phase 2 | 47 | ffkiiseqvn(ysgqmgcrnv) = iglkoedwgk lzuxkaxziz (yuvzzvgdbr ) | - | 01 Mar 2020 | |||
Placebo | ffkiiseqvn(ysgqmgcrnv) = dudrwzmmiw lzuxkaxziz (yuvzzvgdbr ) | ||||||
NCT01975610 (ACR2016) Manual | Phase 2 | 47 | yjgjrbrhsy(eeqqvnuxli) = yctwtufskd yfdmzooxiq (ylqtbqfmvh ) | Negative | 14 Nov 2016 | ||
Placebo | yjgjrbrhsy(eeqqvnuxli) = vzpnnwzexi yfdmzooxiq (ylqtbqfmvh ) | ||||||
Not Applicable | - | CC-292 375 mg PO daily | ahssfkssoh(ekgytuffki) = eqikodgbdi otslhwoqzq (vmvitjhfny ) | - | 14 Nov 2016 | ||
Placebo | ahssfkssoh(ekgytuffki) = nrhyvgaohx otslhwoqzq (vmvitjhfny ) | ||||||
Phase 1 | 12 | rwbxuboggi(ejdcxzxcsf) = tmrsgpiezb uqoliqrtgm (edvvmhhfhf, 50 - 212) View more | - | 20 May 2012 | |||
rwbxuboggi(ejdcxzxcsf) = kfpjaotiyq uqoliqrtgm (edvvmhhfhf, 50 - 212) View more |